For its fourth fiscal quarter (ending December 31), OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) has reported a 15% increase in E.P.S. from $1.26 a year ago to $1.45 in the current quarter. E.P.S. were $6.69 for the latest four quarters through December 31 versus $5.24 for the same period a year ago — an increase of 28%.
Recent Price Action
OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) stock declined by -3.9% on 2/26/25. The shares closed at $288.03. Moreover, exceptionally high trading volume at 219% of normal accompanied the decline. The stock has been strong relative to the market over the last nine months but has declined -1.8% during the last week.
Current PriceTarget Research Rating
VERISK ANALYTICS INC has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. VERISK ANALYTICS INC has a slightly negative Appreciation Score of 33 and a neutral Power Rating of 52, with the Negative Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment